Coleman, K. K. L., Berry, S., Cummings, J., Hsiung, G.-Y. R., Laforce, R., Huey, E., Ducharme, S., Tartaglia, M. C., Mendez, M. F., Onyike, C., Domoto-Reilly, K., Masellis, M., Herrmann, N., Porsteinsson, A., Detry, M. A., Stewart, C., Bosse, A. L., McGlothlin, A., Dias, B., … Finger, E. C. (2025). Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial. The Lancet Neurology, 24(2), 128–139. https://doi.org/10.1016/s1474-4422(24)00456-3

Mougari, S., Favède, V., Predella, C., Reynard, O., Durand, S., Mazelier, M., Pizzioli, E., Decimo, D., Bovier, F. T., Lapsley, L. M., Castagna, C., Lieberman, N. A. P., Noel, G., Mathieu, C., Malissen, B., Briese, T., Greninger, A. L., Alabi, C. A., Dorrello, N. V., … Horvat, B. (2025). Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity. Communications Biology, 8(1). https://doi.org/10.1038/s42003-025-07491-4